Levalbuterol toxicity: no reason to be jittery

Biswas A.K., Fruedenthal W.C.

Source: Eur Respir J 2003; 21: 1081
Journal Issue: June

PDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Biswas A.K., Fruedenthal W.C.. Levalbuterol toxicity: no reason to be jittery. Eur Respir J 2003; 21: 1081

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Cleaning agents: how they look like and how might they cause respiratory harm?
Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health?
Year: 2018

Marijuana and the lung: hysteria or cause for concern?
Source: Breathe, 14 (3) 196; 10.1183/20734735.020418
Year: 2018

Paracetamol use and the risk of wheeze: causation or bias?
Source: Annual Congress 2009 - Early life and childhood asthma - new results from old birth cohorts
Year: 2009

What is this thing called somnolence?
Source: Eur Respir J 2011; 37: 7-8
Year: 2011

Theophylline again? Reasons for believing
Source: Eur Respir J 2009; 34: 5-6
Year: 2009

The side-effects of TB therapy: myth and reality
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005

Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

LATE-BREAKING ABSTRACT: Tackling the burden of chronic cough: A dose escalation study of AF-219
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016

Breathlessness: respiratory, cardiac, or something else?
Source: International Congress 2015 – Primary Care Programme
Year: 2015

Residual excessive sleepiness in long term CPAP-treated patients: a leak problem?
Source: International Congress 2018 – New diagnostic tools for sleep and breathing and healthcare provision options
Year: 2018

Immunotherapy: when, who and which drug?
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018

Opioids in COPD: a cause of death or a marker of illness severity?
Source: Eur Respir J 2016; 48: 1520-1521
Year: 2016

Opioids in COPD: a cause of death or a marker of illness severity?
Source: Eur Respir J 2016; 48: 1521-1522
Year: 2016

Fooling the brain to alleviate dyspnoea
Source: Eur Respir J, 50 (2) 1701383; 10.1183/13993003.01383-2017
Year: 2017

New inhaler devices: the good, the bad, and the ugly
Source: International Congress 2015 – Inhaled drugs: within and beyond the lungs
Year: 2015

Deprescribing of inhaled corticosteroids in patients with COPD with mild or moderate airflow limitation: what do patients think?
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Difficult-to-wean patients: can we avoid the problem?
Source: ERS Skills Course 2016
Year: 2016

A case of unexplained dyspnoea: when lung function testing matters!
Source: Breathe, 14 (4) 325; 10.1183/20734735.025018
Year: 2018

Treating non-adherence: the rest is pointless if the drugs stay in the cupboard!
Source: International Congress 2017 – Cystic fibrosis in children and adults: treatment dilemmas
Year: 2017